Ipamorelin
- Status
- Phase 2, , not approved for human use
- Evidence
Small human trials, graded on 2 research benches
Ipamorelin is a selective pentapeptide ghrelin receptor (GHS-R1a) agonist — one of the most studied growth hormone secretagogues (GHS) in the biohacking community and the modern companion to CJC-1295 / MOD-GRF 1-29.
Reviewed
01Overview
What Ipamorelin is
Its five-amino-acid sequence (Aib-His-D-2Nal-D-Phe-Lys-NH₂) was discovered by Novo Nordisk and published in 1998 as "the first selective growth hormone secretagogue" ([Raun et al., 1998]).
Read the full overviewShow less
The word "selective" is the critical term. Earlier GHS peptides (hexarelin, GHRP-6, GHRP-2) all release GH but also raise cortisol, prolactin, and ACTH — because the ghrelin receptor is expressed on corticotrophs and lactotrophs as well as somatotrophs. Ipamorelin is the GHS peptide best known for producing no significant rise in cortisol or ACTH in conscious swine, even at doses more than 200-fold above the GH-releasing ED50, and no change in prolactin, LH, FSH or TSH (Raun et al., 1998). No human trial has tested that selectivity. This makes it clean of ACTH and cortisol effects in swine — you get the anabolic GH/IGF-1 axis activation without the stress-hormone and mammary-tissue side effects that plague GHRP-2 and GHRP-6.
Ipamorelin has an in vivo half-life of approximately 2 hours in humans ([Gobburu et al., 1999]). After a 15-minute intravenous infusion in healthy men, GH rose in a single episode that peaked at about 40 minutes (Gobburu et al., 1999); no published human study has measured the response to a subcutaneous injection. Typical dosing is 100-300 mcg SC, 1-3 times daily, almost always co-administered with a GHRH analog (MOD-GRF 1-29 or sermorelin) to exploit the well-documented ghrelin × GHRH synergy — the two pathways converge on pituitary somatotrophs through distinct second messengers, and in normal men GHRP-6 given with GHRH released GH synergistically (Bowers et al., 1990); no published human study has paired ipamorelin itself with a GHRH analog.
Clinical development by Helsinn Therapeutics (licensed from Novo Nordisk) reached Phase 2 for post-operative ileus, where IV ipamorelin missed the primary endpoint: median time to a first tolerated meal was 25.3 h versus 32.6 h on placebo (p = 0.15) (Beck et al., 2014). A second, larger Phase 2 in 320 patients (NCT01280344) was completed in 2014 with no results posted. Development for that indication was subsequently halted, and ipamorelin is not FDA-approved for any indication. It remains widely available as a compounding-pharmacy peptide and research-use reagent.
See our Ipamorelin Dosage Guide and Reconstitution Tool for protocol specifics. The standard stack partner is documented at /compound/cjc-1295.
How it works
Ipamorelin acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor activated by endogenous ghrelin - the "hunger hormone" secreted primarily by P/D1 cells in the gastric fundus. The distinguishing feature of ipamorelin among GHS peptides is its receptor specificity profile, which explains its clean side-effect profile.
Read the full mechanismShow less
1. GHS-R1a agonism (Gq/11 / PLC / IP / Ca pathway)
- GHS-R1a is a Class A G-protein-coupled receptor expressed on pituitary somatotrophs, hypothalamic arcuate-nucleus neurons, and (at lower density) gastric cells, pancreatic islets, and cardiomyocytes
- Ligand binding activates Gq/11, triggering phospholipase-C, which cleaves PIP into IP and DAG
- IP mobilizes intracellular Ca; DAG activates PKC
- Net effect: depolarization of the somatotroph and rapid exocytosis of preformed GH granules
- GH rise is detectable within 15 minutes and peaks at 30-60 minutes post-injection
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH) that releases GH from pituitary somatotrophs with an EC of ~1.3 nM in vitro - comparable in potency and efficacy to GHRP-6, but with a dramatically different selectivity profile at secondary sites (Raun et al., 1998).
2. The "selective" property - why ipamorelin is different from GHRP-2 / GHRP-6 / hexarelin
All GHS peptides activate GHS-R1a, but the earlier generation (hexarelin, GHRP-6) also cross-reacted with adjacent receptors on corticotrophs and lactotrophs, producing:
- Cortisol elevation (via ACTH release)
- Prolactin elevation
- ACTH elevation
In conscious swine, ipamorelin did not raise ACTH or cortisol beyond the levels seen after GHRH stimulation, even at doses more than 200-fold higher than its ED50 for GH release, whereas GHRP-6 and GHRP-2 raised ACTH and cortisol; none of the three changed FSH, LH, prolactin or TSH (Raun et al., 1998). This selectivity - established in animal studies rather than a human comparison trial - is the main reason ipamorelin became the GHS peptide of choice for long-term biohacking protocols; the absence of cortisol elevation means it can be stacked without compromising recovery, immune function, or sleep architecture.
3. Synergy with GHRH analogs (the foundation of the GHS stack)
The standard biohacking protocol pairs ipamorelin with a GHRH analog (most commonly MOD-GRF 1-29 / CJC-1295 without DAC) because the two signaling pathways converge on the same pituitary cell through different second messengers:
| Pathway | Receptor | G-protein | Second Messenger | Effect on Somatotroph |
|---|---|---|---|---|
| Ipamorelin | GHS-R1a | Gq/11 | IP / Ca / DAG-PKC | Depolarization + exocytosis |
| MOD-GRF 1-29 | GHRHR | Gs | cAMP / PKA / CREB | Gene transcription + granule mobilization |
Dual activation is expected to produce a larger GH pulse than either agent alone: GHRP-6 given with GHRH released GH synergistically in normal men (Bowers et al., 1990), and with GHRP-2 a combined response that was additive at first became synergistic during chronic dosing (Bowers, 1996); no published human study has paired ipamorelin itself with a GHRH analog. This is why GHRH-only or ghrelin-only protocols are suboptimal and nearly all clinical and research protocols use the combination.
4. Pulsatile release preserves physiology
Because ipamorelin clears in ~2 hours, each injection produces a discrete GH pulse that is reabsorbed into the body's normal pulsatile GH architecture. Between pulses, somatostatin (GHIH) can appropriately suppress GH - preserving negative feedback and preventing the receptor desensitization seen with sustained-release analogs like CJC-1295 with DAC.
5. Downstream effects: IGF-1, body composition, sleep
- Acute GH pulse hepatic IGF-1 synthesis (peaks at ~24h post-dose)
- IGF-1 drives muscle protein synthesis, cartilage deposition, and lipolysis in adipose tissue
- Repeated dosing would be expected to raise IGF-1, but the 30-80% rise within 2-4 weeks often quoted is not in the review it was cited to, which does not discuss ipamorelin (Sigalos & Pastuszak, 2018); the human pharmacokinetic study measured growth hormone, not IGF-1, after single infusions (Gobburu et al., 1999)
- Proposed secondary effects, none measured in the published human ipamorelin trials: deeper slow-wave sleep (GH pulses physiologically occur during SWS), faster wound and connective tissue repair, and lean-mass gains; a 2020 review of GH secretagogues in hypogonadal men found clinical efficacy data largely lacking (Sinha et al., 2020)
6. Secondary physiologic effects (ghrelin-receptor biology)
Because GHS-R1a is expressed beyond the pituitary, chronic ipamorelin administration has minor effects on:
- Appetite - generally mild increase (much less than native ghrelin due to the shorter duration of action)
- Gastric motility - accelerates gastric emptying; this is why it was investigated for post-operative ileus
- Cardiovascular - cardioprotective and anti-inflammatory signaling in some animal models
Studied for
- Growth hormone deficiency
- Body composition
- Aging
- Bone density
Benefits listed
- Increased GH pulse amplitude (selective somatotroph activation)
- Elevated IGF-1 with consistent dosing (expected from GH release)
- Improved slow-wave sleep architecture
- No ACTH or cortisol rise beyond GHRH levels in conscious swine, where GHRP-6 and GHRP-2 raised both (no human comparison; PMID 9849822)
Show 4 moreShow less
- Accelerated connective tissue and wound repair
- Lean mass gain or fat loss (not measured in any human ipamorelin trial; a 2020 review of GH secretagogues in hypogonadal men found clinical efficacy data largely lacking, PMID 32257855)
- Enhanced recovery between training sessions
- Synergistic effect with CJC-1295 / MOD-GRF 1-29
02Research
Free with emailWhat the research shows
Graded on 2 research benches
Reference pages that put Ipamorelin next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
03Safety
Ipamorelin side effects and interactions
Side effects
Common
- Transient head rush or flushing immediately post-injection
- Mild injection site irritation
- Transient hunger increase (ghrelin pathway activation)
- Water retention during initial 1-2 weeks of use
- Mild tingling or numbness in extremities (transient)
Serious events
- Potential to accelerate growth of undiagnosed malignancy via GH/IGF-1 axis
- Carpal tunnel syndrome with prolonged supraphysiological GH/IGF-1 levels
- Insulin resistance with chronic use — monitor fasting glucose and HbA1c
- No human clinical trials completed beyond early-phase studies
Who should not use it
Contraindications
Absolute contraindications
- Active malignancy — GH and IGF-1 are trophic factors for multiple cancer cell lines. While ipamorelin-specific cancer data does not exist, the GH/IGF-1 axis is implicated in colorectal, prostate, breast, and hepatocellular cancer progression ([Renehan et al., 2004]). Do not use during active cancer treatment or within 5 years of complete remission without oncologist clearance
- Known or suspected pituitary tumor / acromegaly — superimposing exogenous secretagogue on an already-hyperactive somatotroph axis can accelerate tumor growth and precipitate acromegalic complications
- Active diabetic retinopathy — GH elevation can worsen proliferative retinopathy; absolute contraindication until retinopathy is stabilized
- Pregnancy or breastfeeding — no safety data; do not use
- Age <18 — no pediatric safety data; pediatric GHD is managed with prescription GHRH analogs (sermorelin) under endocrinology supervision, not biohacking protocols
Read all the contraindications and cautionsShow less
Relative contraindications (consult physician before use)
- Type 2 diabetes or pre-diabetes — GH elevation impairs insulin sensitivity; use requires careful glucose monitoring and may accelerate progression in borderline cases
- Uncontrolled hypertension — fluid retention can exacerbate blood pressure
- History of carpal tunnel syndrome — fluid retention and connective tissue expansion can worsen symptoms
- Hypothyroidism — thyroid status affects GH axis; optimize thyroid first
- History of pituitary or hypothalamic surgery or radiation — altered GHRH/ghrelin receptor status; unpredictable response
Drug interactions
- Insulin and oral hypoglycemics — ipamorelin's effect on glucose tolerance may require dose adjustments of antidiabetic medications
- Corticosteroids — chronic systemic corticosteroids suppress the GH axis and blunt ipamorelin response
- Recombinant GH (Somatropin) — redundant; do not combine
- Other GHS peptides — do not stack (see stacking notes)
Monitoring requirements for users
- Baseline labs: Fasting glucose, HbA1c, IGF-1, complete metabolic panel, CBC, PSA (men >40), full thyroid panel
- 4-6 weeks into dosing: Fasting glucose, IGF-1 (confirm within age-appropriate range)
- End of each cycle: Full panel; look for HbA1c creep, PSA changes, IGF-1 elevation above age-adjusted ULN
Discontinuation criteria
Stop ipamorelin and consult a clinician if you develop:
- Persistent peripheral edema or facial swelling
- New or worsening carpal tunnel symptoms
- IGF-1 levels >300 ng/mL (supraphysiologic in most adults)
- Fasting glucose persistently >110 mg/dL or HbA1c rising >0.4 points
- Any new palpable mass, changing mole, or unexplained weight loss (cancer workup indicated)
- Severe headache, visual changes (rule out pituitary pathology)
Interactions
5 pairings in our record: 1 with a caution and 4 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.
GHRP-2
CautionRedundant GHRP mechanisms — choose one
CJC-1295
SynergisticThe most popular GH stack — clean GH pulses without excess hunger or cortisol
MK-677
SynergisticOral GHS + injectable GHRP for sustained GH elevation
Sermorelin
SynergisticGHRH analog + GHRP for natural GH pulse amplification
Tesamorelin
SynergisticBoth promote GH release through complementary pathways
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
Need bloodwork before starting?
Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.
04Dosing
Free with emailIpamorelin dosage and protocols
- Dose range
- 100-300 mcg subcutaneous 1-3x daily (most commonly 200-300 mcg pre-bedtime); often combined with CJC-1295 without DAC at 100-300 mcg
- Dosing
- 1–3 times daily; most commonly once at bedtime
- Common vials
- 2mg, 5mg
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- Dose, route, how often and how long
- A titration schedule
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
05Prices
Ipamorelin prices
5 listings from 3 vendors, opening in the Featured order.
- Pack prices
- $24.99 to $59.99
- Lowest per mg
- $4.20/mg
- Vendors
- 3
- Listings
- 5 (vial)
Prices as the vendors list them, last recorded 8 October 2026.
| Vendor | Product | Price | Buy |
|---|---|---|---|
Ipamorelin vial, 1 vial In stock | $59.99 No mg count | Buy Ipamorelin at Disguised Alpha | |
Ipamorelin 5mg vial, 1 vial Out of stock | $7.00/mg $35.00 | View Ipamorelin 5mg at Ion Peptide | |
Ipamorelin 10mg vial, 1 vial In stock | $4.20/mg $42.00 Lowest per mg | Buy Ipamorelin 10mg at Ion Peptide | |
Ipamorelin 2mg vial, 2mg vial In stock | $12.49/mg $24.99 | Buy Ipamorelin 2mg at Half Nattys | |
Ipamorelin 5mg vial, 5mg vial In stock | $7.00/mg $34.99 | Buy Ipamorelin 5mg at Half Nattys |
Vendors selling Ipamorelin(3: trust score, certificates, payment, shipping)
- Half Nattys2 listings, from $24.99
Trust Score 50/100, 0 of 31 certificate records read, pays by card, crypto, Zelle, ships to the US
- Ion Peptide2 listings, from $35.00
Trust Score 70/100, no certificate records on file, pays by card, crypto, ACH, ships to the US, international destinations
- Disguised Alpha1 listing, from $59.99
Trust Score 50/100, 0 of 36 certificate records read, pays by card, crypto, bank transfer, ships to the US, the EU, the UK
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors
Price history(3 days with a recorded price)
06Chemistry
Chemistry and structure
- Molecular formula
- C38H49N9O5
- Molecular mass
- 711.86 g/mol
- CAS number
- 170851-70-4
- IUPAC name
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Amino acid sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
08Questions
Frequently asked questions
What makes ipamorelin different from other GHS peptides like GHRP-2 or GHRP-6?
Ipamorelin was the first GHS peptide shown to release growth hormone without elevating cortisol, prolactin, ACTH, LH, FSH, or TSH - in the original animal studies it remained selective even at doses more than 200-fold above its GH-releasing dose (Raun et al., 1998, in swine). Earlier GHS peptides (GHRP-2, GHRP-6, hexarelin) also stimulate corticotrophs and lactotrophs, producing cortisol and prolactin spikes that can compromise recovery, immune function, and (in men) breast tissue. This 'selective' property is the reason ipamorelin became the default GHS peptide for modern biohacking protocols. Note that this selectivity was established in animals, not in a human comparison trial.
Do I need to stack ipamorelin with CJC-1295 or MOD-GRF 1-29?
Functionally, yes. Ipamorelin alone produces a modest GH pulse. Paired with a GHRH analog (MOD-GRF 1-29 / CJC-1295 without DAC), the GH pulse is expected to be larger, because the two signaling pathways converge on the same pituitary somatotroph through distinct second messengers (Gq/PLC/IP vs Gs/cAMP/PKA); no published human study has paired ipamorelin with a GHRH analog. Nearly all clinic and community protocols use the combination; standalone ipamorelin is primarily used in weeks 1-4 of a beginner protocol to confirm tolerance before adding the GHRH partner.
What's the correct ipamorelin dose and how often should I inject?
Therapeutic range is 100-300 mcg subcutaneously per injection, 1-3x daily. Common protocols: (1) Sleep / recovery focus - 200 mcg pre-bed once daily; (2) Body composition - 200 mcg + 100 mcg MOD-GRF 1-29 twice daily (pre-bed + morning fasted); (3) Advanced - 100-200 mcg tri-daily. Dose-response plateaus above 300 mcg per injection - more frequent smaller pulses outperform larger single doses. All doses must be in a fasted state (>=2 hours post-meal); elevated insulin blunts GH response by 50-70%.
Why must I inject ipamorelin in a fasted state?
Elevated insulin suppresses pituitary GH release through increased somatostatin tone and reduced somatotroph sensitivity. Post-meal dosing can cut the GH pulse by 50-70%. The two reliably fasted windows are pre-bed (2+ hours after the evening meal) and morning on waking (before the first meal). Carbohydrates and protein both elevate insulin - fat alone has minimal effect but a pure fasted window is cleanest. Alcohol independently suppresses GH; avoid within 4 hours of dosing.
How long does it take to see results from ipamorelin?
Effects appear on different timelines: (1) Sleep quality and deeper SWS within 1-3 nights; (2) Recovery between training sessions within 1-2 weeks; (3) IGF-1 elevation measurable at 4 weeks; (4) Body composition changes (lean mass , visceral fat ) visible at 8-12 weeks with consistent dosing; (5) Connective tissue / injury repair acceleration within 4-6 weeks, often used alongside BPC-157 and TB-500. Note that effects are dose-dependent - 200 mcg once daily will produce subtler changes than the 2-3x daily stacked protocol.
What are the actual side effects of ipamorelin?
Often called the cleanest profile of any GHS peptide, a label that rests on one comparison in swine (Raun et al., 1998). Common: injection site reactions, transient hunger (less than GHRP-6), vivid dreams, brief head-heaviness 10-30 min post-injection. Uncommon: mild water retention, hand paresthesias (early water-retention sign), joint stiffness as IGF-1 rises. Rare: insulin resistance at high chronic doses, carpal tunnel symptoms. In swine, ipamorelin did not raise cortisol or ACTH beyond GHRH levels while GHRP-2 and GHRP-6 did, and none of the three changed prolactin; no human study has compared them (Raun et al., 1998). Most side effects are dose-dependent - stay at or below 300 mcg per injection and cycle (8-12 weeks on / 4-6 weeks off) to minimize cumulative burden.
Is ipamorelin safer than injecting actual growth hormone (somatropin)?
Mechanistically, yes - but with caveats. Ipamorelin amplifies the body's own pulsatile GH release via the pituitary, preserving negative feedback (somatostatin can still suppress GH between pulses) and physiologic pulse architecture. Exogenous somatropin bypasses the pituitary and produces tonic, non-pulsatile GH elevation, which carries a higher burden of insulin resistance, edema, and theoretical cancer-axis concerns. However, both share the GH/IGF-1 safety envelope: active malignancy, diabetic retinopathy, and pituitary tumors are absolute contraindications for both. Ipamorelin is NOT FDA-approved; somatropin is FDA-approved for specific indications. Neither is a replacement for the other - they occupy different therapeutic niches.
Does ipamorelin affect appetite or cause weight gain?
Mildly. Ipamorelin activates the same receptor (GHS-R1a) as ghrelin, which is involved in hunger signaling. In practice the appetite effect is much smaller than GHRP-6 because ipamorelin's ~2-hour half-life limits tonic activation of hypothalamic feeding neurons. Most users report minor evening hunger at the pre-bed dose - this can be managed by injecting 20-30 min before lights-out so sleep supersedes the appetite signal. Weight typically goes UP on ipamorelin due to (a) increased lean body mass from GH/IGF-1 elevation and (b) modest fluid retention; fat mass typically goes DOWN. Tracking body composition (DEXA or bioimpedance) is more useful than scale weight.
Can I combine ipamorelin with semaglutide, TRT, BPC-157, or other peptides?
Yes, with different rationales. Semaglutide / tirzepatide: ipamorelin + MOD-GRF 1-29 preserves lean mass during the GLP-1-induced caloric deficit; this is a common recomposition stack. TRT: fully complementary - HPG and GH axes are independent; combined use is standard in integrative clinics. BPC-157 / TB-500: synergistic for connective tissue repair - GH/IGF-1 provides the systemic anabolic signal that BPC-157 local repair mechanisms can leverage. NAD+ / NMN: mitochondrial support for the increased protein synthesis demand. DO NOT stack with other ghrelin-receptor agonists (GHRP-2/6, hexarelin, MK-677) - redundant at the receptor - or with exogenous recombinant GH (mechanistically defeating).
Is ipamorelin legal and where does it come from?
Ipamorelin is not FDA-approved for any indication in the United States. Originally discovered at Novo Nordisk, it was later developed for post-operative ileus, but that program reached only a Phase 2 proof-of-concept trial that missed its primary endpoint (median time to first tolerated meal 25.3 h vs 32.6 h on placebo, p=0.15) and development was discontinued (Beck et al., 2014). It is sold as a research chemical (not for human use) and is also dispensed by some compounding pharmacies and anti-aging / integrative clinics on a prescription basis. Legal status for personal use varies by jurisdiction - always verify local regulations. Quality varies substantially between suppliers; third-party HPLC and mass-spec testing is the only way to verify identity and purity. See our Best Peptide Vendors 2026 guide for vetted sources.
How many vendors sell Ipamorelin, and what does it cost per mg?
3 of the vendors BodyHackGuide tracks list Ipamorelin (5 listings). Among BodyHackGuide's Ipamorelin listings recorded as in stock with a milligram count, the lowest price per milligram is $4.20/mg at Ion Peptide and the median is $7.00/mg. The Ipamorelin prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Ipamorelin listing is dated 8 October 2026.
Which vendors have third-party COAs for Ipamorelin on file at BodyHackGuide?
BodyHackGuide holds 139 third-party certificate records for Ipamorelin, from ResearchChemHQ and Half Nattys. An editor has read 1 of BodyHackGuide's 139 certificate records for Ipamorelin and recorded the laboratory, the compound and the test date as printed on each. The laboratories named on BodyHackGuide's Ipamorelin certificate records are Janoshik Analytical and Freedom Diagnostics Testing, and the newest test date on them is 6 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.
Related
Articles on Ipamorelin
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.


